Epoprostenol for primary pulmonary hypertension.
Epoprostenol sodium (Flolan-Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension.
D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D011464:Epoprostenol